Larotaxel (dihydrate)

Larotaxel (dihydrate) (XRP9881 (dihydrate) ), a new taxane compound prepared by partial synthesis from 10-deacetyl baccatin III, is active against tumors[1].

Product Specifications

CAS Number

[192573-38-9]

Product Name Alternative

XRP9881 (dihydrate)

UNSPSC

12352005

Hazard Statement

H301-H311-H319-H341-H360-H362-H372

Target

Microtubule/Tubulin

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/larotaxel-dihydrate.html

Solubility

10 mM in DMSO

Smiles

O=C([C@]1([H])OC(C)=O)[C@@]23[C@@]([C@@H]([C@@]4(O)C(C)(C)C1=C([C@H](OC([C@H](O)[C@H](C5=CC=CC=C5)NC(OC(C)(C)C)=O)=O)C4)C)OC(C6=CC=CC=C6)=O)([H])[C@]7([C@@](OC7)([H])C[C@@H]2C3)OC(C)=O.O.O

Molecular Formula

C45H57NO16

Molecular Weight

867.93

Precautions

P260-P263-P264-P270-P280-P302+P352-P305+P351+P338-P330-P361+P364-P405-P501

References & Citations

[1]Liang X, et al. Degradation kinetics of larotaxel and identification of its degradation products in alkaline condition. J Pharm Anal. 2017;7 (2) :118-122.